APROVEL FILM-COATED TABLET 300 MG

SANOFI WINTHROP INDUSTRIE (FRANCE)🇸🇬 Health Sciences Authority

Approval Date: Apr 6, 1999
Approval ID: 5615a1d0c7c29db0
Company: SANOFI WINTHROP INDUSTRIE (FRANCE)
Type: Therapeutic

Approval Details

Approval Id: 5615a1d0c7c29db0
Drug Name: APROVEL FILM-COATED TABLET 300 MG
Product Name: APROVEL FILM-COATED TABLET 300 MG
Approval Number: SIN10862P
Approval Date: 1999-04-06
Registrant: SANOFI-AVENTIS SINGAPORE PTE. LTD.
Licence Holder: SANOFI-AVENTIS SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET, FILM COATED
Dosage: Posology and method of administration The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Aprovel at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years. In patients insufficiently controlled with 150 mg once daily, the dose of Aprovel can be increased to 300 mg, or other anti-hypertensive agents can be added. In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Aprovel (see Interaction with other medicinal products and other forms of interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. The demonstration of renal benefit of Aprovel in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Renal impairment: no dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis. Intravascular volume depletion: volume and/or sodium depletion should be corrected prior to administration of Aprovel. Hepatic impairment: no dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment. Elderly patients: although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for the elderly. Children: the safety and efficacy of Aprovel have not been established in children.
Route Of Administration: ORAL
Indication Info: Therapeutic indications Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive drug regimen (see Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications: Contraindications Hypersensitivity to the active substance or to any of the excipients listed in List of excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Second and third trimester of pregnancy (see Special warnings and special precautions for use and Fertility, pregnancy and lactation – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). The concomitant use of Aprovel with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) < 60 ml/min/1.73 m2) (see Interaction with other medicinal products and other forms of interaction and Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Atc Code: C09CA04
Atc Item Name: irbesartan
Pharma Manufacturer Name: SANOFI-AVENTIS SINGAPORE PTE. LTD.
Company Detail Path: /organization/sanofi-aventis-singapore-pte-ltd

Active Ingredients

IRBESARTAN

300.00 mg

IRBESARTAN

300.00 mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Apr 6, 1999

Approval ID

5615a1d0c7c29db0

Type

Therapeutic

Back to HSA Approvals